Adipokine Chemerin Stimulates Progression of Atherosclerosis in ApoE\textsuperscript{−/−} Mice

Huadong Liu,\textsuperscript{1} Wei Xiong,\textsuperscript{1} Yu Luo,\textsuperscript{2} Hua Chen,\textsuperscript{3} Yaqiong He,\textsuperscript{1} Yuanzhi Cao,\textsuperscript{1} and Shaohong Dong\textsuperscript{1}

\textsuperscript{1}Department of Cardiology, Shenzhen People’s Hospital, The Second Affiliated Hospital of Jinan Medical College, Shenzhen 518020, China
\textsuperscript{2}Department of Gerontology, Shenzhen People’s Hospital, The Second Affiliated Hospital of Jinan Medical College, Shenzhen 518020, China
\textsuperscript{3}Department of Emergency, Shenzhen People’s Hospital, The Second Affiliated Hospital of Jinan Medical College, Shenzhen 518020, China

Correspondence should be addressed to Shaohong Dong; dshsyxnk@163.com

Received 26 May 2019; Revised 31 July 2019; Accepted 3 October 2019; Published 31 October 2019

Academic Editor: Koichiro Wada

Copyright ©2019 Huadong Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Vascular remodeling is the most critical pathogenesis of atherosclerosis. Adipokine chemerin was known for its relationship with obesity as well as metabolism. Most recently, chemerin was found to play a crucial role in the pathologic process of cardiovascular diseases including coronary heart disease. In this study, we surveyed the role of chemerin in progression of atherosclerosis in ApoE\textsuperscript{−/−} mice. Objective. To investigate the relationship between chemerin and progression of atherosclerosis in ApoE\textsuperscript{−/−} mice and its mechanism. Methods. 8-week-old ApoE\textsuperscript{−/−} mice were fed with high-fat diet to induce the atherosclerosis model. Adenoviruses were transfected for knockdown or overexpression of chemerin gene into aorta. Serums and aortic tissues of ApoE\textsuperscript{−/−} mice were obtained after feeding high-fat diet for 16 weeks. HE staining and oil red staining were performed to evaluate aortic plaque. ELISA was performed to explore serum levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and transforming growth factor-β1 (TGF-β1). Real-time PCR and western blotting were carried out to investigate the mRNA and protein levels of chemerin, nuclear factor-κB p65 (NF-κB p65), proliferating cell nuclear antigen (PCNA), phosphorylated p38 mitogen-activated protein kinase (p-p38-MAPK), phosphorylated c-Jun N-terminal kinase (p-JNK), and phosphorylated extracellular signal regulated kinase 1/2 (p-ERK 1/2). Result. Aortic plaque formation was significantly induced by high-fat diet in ApoE\textsuperscript{−/−} mice. Simultaneously, elevated serum levels of TNF-α and IL-1β and elevated mRNA and protein levels of chemerin, NF-κB p65, PCNA, p-p38-MAPK, p-JNK, and p-ERK 1/2 were found in ApoE\textsuperscript{−/−} mice. After aortic chemerin gene was inhibited by adenovirus, aortic atherosclerosis induced by high-fat diet was significantly meliorated, serum levels of TNF-α and IL-1β decreased, mRNA and protein levels of NF-κB p65, PCNA, p-p38-MAPK, p-JNK, and p-ERK 1/2 decreased simultaneously.

Conclusion. Our study revealed that chemerin stimulated the progression of atherosclerosis in ApoE\textsuperscript{−/−} mice.

1. Introduction

Coronary heart disease and stroke originated from atherosclerosis are the primary causes of death worldwide [1, 2]. Despite great efforts have been made, the pathogenic molecular mechanisms of atherosclerosis is not clearly clarified. It was extensively agreed that atherosclerosis is a chronic progressive inflammatory and immune disorder [3–6]. Adipokines are cytokines secreted by adipose tissue, which play a critical role in adipocyte differentiation and maturation. Under pathological states such as tissue damage and inflammation, large amounts of adipokines are synthesized and secreted, which are not only associated with metabolic diseases such as obesity and type 2 diabetes but also contribute to the development of cardiovascular diseases such as coronary heart disease [7]. Chemerin, a latest discovered adipokine, was found to play an important role in cardiovascular diseases [8]. Evidences showed that circulating
levels of chemerin significantly increased in rheumatoid arthritis patients accompanied with cardiovascular disease, gestational hypertension, metabolic syndrome, dilated cardiomyopathy, and advanced carotid stenosis [9–13]. It also was identified by autopsy that chemerin was expressed in adipose tissue around the human coronary arteries, vascular smooth muscle cells (VSMCs), and foam cells in coronary artery lesions, the level of which was positively correlated with the severity of coronary atherosclerosis [14]. However, it is less known about the mode and mechanism of chemerin involving in the cardiovascular diseases including atherosclerosis and its complications.

Vascular remodeling is the crucial pathological process in atherosclerosis and restenosis after angioplasty. VSMCs and endothelial cells are primary cell types in blood vessel walls, which are fundamental to vascular homeostasis [15, 16]. In a previous study, we found that circulating chemerin levels increased after carotid balloon injury, and knockdown of chemerin significantly inhibited the VSMCs proliferation in vitro as well as prohibited carotid neointimal hyperplasia in vivo after angioplasty [17]. Further investigation revealed that knockdown of chemerin receptor, chemokine-like receptor 1 (CMKLR1), inhibited the proliferation and migration of VSMCs [18].

In the present study, we explored the role of chemerin in initiation and progression of atherosclerosis in apolipoprotein-E deficient (ApoE−/−) mice to better understand its duty and the underlying mechanism in atherosclerosis and other cardiovascular diseases.

2. Materials and Methods

2.1. Ethics Statement. This study was strictly performed according to the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was sanctioned by the Animal Ethics Committee of the Shenzhen People’s Hospital. All efforts have been made to reduce animal suffering.

2.2. Adenovirus Construction. As described in our previous study [19], the synthesized chemerin gene DNA was digested by PstI and HindIII to generate the target sequence, which was integrated into the adenoviral vector pDC316-mCMV-ZsGreen. Simultaneously, the synthetic shRNA interfering chemerin gene was digested by Pst I and BamH with the pDC316-ZsGreen-shRNA vector. Chemerin shRNA sequence, forward: GCCACATCAAAACCAAGGATCAAGATCCCGTTTGGTATGGCTTTTTG, reverse: GATCCAAAAAGCAACTCTACAAACGAGGACTCTTGATCCGGTTTGGTATGGCTTTTTG, the digest product was harvested, and the shRNA was cloned into the pDC316-ZsGreen-shRNA vector. Two above recombinant plasmids were transfected, respectively; subsequently, the positive recombinant plasmids were picked and identified. The recombinant adenovirus plasmid overexpression of chemerin gene as well as knockdown of chemerin gene were transfected into the 293a cells, respectively, with the adenovirus packaging plasmid to generate the recombinant adenoviruses. The adenoviruses were repeatedly harvested and purified to produce the efficient chemerin gene overexpression adenovirus (overexpression) as well as chemerin gene interference adenovirus (knockdown) for further experiments.

2.3. Mice and Diet. 7-week-old male ApoE−/− mice and wild-type C57BL/6J mice were obtained from Vital River Laboratory Animal Technology Co., Ltd (Beijing, China) and housed in specific pathogen-free animal rooms in climate-controlled conditions (22 ± 1°C, 40%–70% humidity) as well as diurnal conditions (12 hour light/dark cycle) with access to food and water ad libitum. After acclimatization for 1 week, 25 ApoE−/− mice were fed high fat diet (40 kcal% fat, 1.25% cholesterol, Research Diets D12108C, USA) and, respectively, sacrificed at 0, 4, 8, 12, and 16 weeks (n = 5 for each group). The wild-type C57BL/6J were fed with low-fat diet (10 kcal% fat, 0% cholesterol, Research Diets D12102C, USA) for 16 weeks (control group, n = 6). Another 36 ApoE−/− mice were fed high fat diet for 16 weeks. In the 8th week, the ApoE−/− mice were injected with the vector (atherosclerosis + vector group, n = 6), the chemerin gene overexpression adenovirus (Atherosclerosis + Overexpression group, n = 6), or chemerin gene knockdown adenovirus (Atherosclerosis + Knockdown group, n = 6), respectively, from caudal vein every 2 weeks until the 16th weeks. The mice of the control group were injected with same volume of PBS in the same manner.

2.4. Aortic Morphology. The thoracic aortas were isolated. These samples were embedded in optimum cutting temperature (OCT) compound (Sakura Fine Technical, Tokyo, Japan) and snap-frozen in liquid nitrogen. OCT-embedded samples were cut serially into cross-sections (5 μm thick). Hematoxylin-eosin staining and oil red O staining were performed to evaluate aortic morphology, respectively. The thickness of neointima and media, lipid area, and plaque area were investigated by calculating the neointima/media ratio and lipid percentage using computer-assisted color image analysis (Image-Pro Plus, version 6.0, Media Cybernetics, Inc., Silver Spring, Maryland, USA).

2.5. Immunofluorescence Assay. Thoracic aortic tissues isolated at different stages were fixed in 4% paraformaldehyde and permeabilized using 0.1% Triton X-100 at room temperature and then blocked by 5% BSA. Slides were incubated with polyclonal rabbit anti-rat chemerin (1:1000, Abcam, UK). Subsequently, tissues were treated with goat anti-rabbit immunoglobulin G (1:500, Invitrogen Life Technologies, USA) and stained by 4′,6-diamidino-2-phenylindole (DAPI). The confocal microscope (Leica, Germany) was employed to capture fluorescence images. All parameters were measured by computer-assisted color image analysis.

2.6. Enzyme-Linked Immunoabsorbent Assay. All blood samples from mice were collected after feeding low-fat diet or high-fat diet for 16 weeks. Serum levels of interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and transforming
growth factor-β1 (TGF-β1) were assessed using an enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer’s protocol (4A Biotech Co., Ltd, China).

2.7. Real-Time PCR. Total RNA was extracted from thoracic aortas and reversed to cDNA using the Transcript cDNA Synthesis Supermix kit (Takara, Japan). Quantitative real-time PCR was performed to assess chemerin, nuclear factor-κB p65 (NF-κBp65), proliferating cell nuclear antigen (PCNA), phosphorylated p38 mitogen-activated protein kinase (p-p38-MAPK), phosphorylated c-Jun N-terminal kinase (p-JNK), and phosphorylated extracellular signal regulated kinase 1/2 (p-ERK 1/2) using the ABI PRISM 7900 Sequence Detection System (Applied Biosystems, USA) with the Top Green qPCR Supermix kit (Takara, Japan). U6 RNA served as an internal control. Primers were as follows: chemerin forward (5′ to 3′) TACAGGTGGCCTGGAGGAGTTC, chemerin reverse CTTCTCCGTTTGGTTTGATTG; NF-κBp65 forward (5′ to 3′) CACGAGTATGCCATCTGGGC, NF-κBp65 reverse (5′ to 3′) AAGCCCTCAAGGAAACAGT; PCNA forward (5′ to 3′) TTTGAGACGCGTCTAC, PCNA reverse (5′ to 3′) GGAGACGTGAGACGAGTCCAT; p-JNK forward (5′ to 3′) GGAATCAAGCACCTTCACTCTG, p-JNK reverse (5′ to 3′) AGTCACCACATAAGGCGTCA TC; p-ERK 1/2 forward (5′ to 3′) AGCGGTTCC-3′p-ERK 1/2 reverse (5′ to 3′) CTGGCTITCTGACCGAGTATGTG, p-ERK 1/2 reverse (5′ to 3′) CAATITAGGTCCTCTY

All primers were synthesized by Sangon (China). The relative expression levels of mRNA were calculated based on the following equation: relative mRNA level = 2−(ΔΔCt sample−ΔΔCt control). All operations were carried out according to the manufacturer’s instructions.

2.8. Western Blotting. Total proteins (20 μg) extracted from thoracic aortas were resolved on 10% SDS-polyacrylamide gels and electrotransferred onto nitrocellulose membranes by electrophoresis. The membranes were blocked in 5% nonfat milk and TBS containing 0.3% Tween-20, subsequently incubated overnight with polyclonal rabbit anti-chemerin (1:1000, Abcam, UK), NF-κBp65 (1:1000, Cell Signaling Technology, USA), PCNA (1:500, Santa Cruz, USA), p-p38-MAPK (1:1000, Santa Cruz, USA), p-JNK (1:1000, Cell Signaling Technology, USA), and β-actin (1:1000, Santa Cruz, USA). The blots were incubated in 1:6000 dilution of goat anti-rabbit horseradish peroxidase-conjugated secondary antibodies. 100 μl ECL solution was added in each sample to detect the protein signal with the Quant RT ECL cold CCD imaging system (General Electric, USA).

2.9. Statistical Analysis. The number of animals was determined based on the previous study [17]. Statistical analyses were performed using SPSS 12.0 (SPSS Inc., USA). The normality of data was first assessed by Shapiro–Wilk testing. The data that obeyed a normal distribution were expressed as mean ± standard error. For relative gene expression, mean value of the control group was defined as 100%. One-way analysis of variance (ANOVA) followed by the Student–Newman–Keuls test were used for statistical analyses. A p value <0.05 was considered statistically significantly.

3. Results

3.1. Chemerin Promoted Aortic Atherosclerosis in ApoE−/− Mice. After being administrated with high-fat diet for 8 weeks, lipid stripes were initially found in the aortic tissue of ApoE−/− mice (Figure 1(a)). The ratio of aortic neointima/media thickness and aortic plaque area at the 8th week were significantly elevated (vs 0 week, P<0.05). Figures 1(b) and 1(c)), the lipid percentage of aortic tissue increased at the 12th week (vs 0 week, P<0.05). Figure 1(d)). The most significant atherosclerotic plaques were found at the 16th week (Figure 1(a)). Compared with the level of ApoE−/− mice in 0 week, serum chemerin started to increase at the 4th week (P<0.05), peaked at the 8th week (P<0.01), and decreased at the 12th week (P<0.01) (Figure 1(e)). Immunofluorescence assay showed that positive staining of chemerin (green fluorescence) was primarily located in the cytoplasm of VSMCs (Figure 1(a)). The positive expression of chemerin in the aortic tissue of ApoE−/− mice was not obvious in the first 8 weeks, which significantly increased at the 12th week (vs 0 week, P<0.05) and peaked at the 16th week (vs 0 week, P<0.01) (Figure 1(f)). A positive correlation was found between aortic chemerin level and the ratio of aortic intima/media thickness (Figure 1(g)).

In the Atherosclerosis + Vector group, the mRNA and protein levels of aortic chemerin were significantly increased (vs control group, P<0.05. Figures 2(b) and 2(c)). Compared with the Atherosclerosis + Vector group, the expression of chemerin in aortic tissues was decreased in the Atherosclerosis + Knockdown group (P<0.01, Figure 2(b), 2(c)) and increased in the Atherosclerosis + Overexpression group (P<0.05, Figures 2(b) and 2(c)). As shown in Figures 2(a), 2(d), and 2(f), the atherosclerotic plaque formation was significantly reduced in the Atherosclerosis + Knockdown group and augmented in the Atherosclerosis + Overexpression group, as compared with the Atherosclerosis + Vector group.

3.2. Chemerin Increased Serum Proinflammatory Cytokine Levels in ApoE−/− Mice. In the atherosclerosis + vector group, serum levels of TNF-α (Figure 3(a)) and IL-1β (Figure 3(b)) significantly increased (P<0.01), whereas the serum level of TGF-β1 (Figure 3(c)) significantly decreased (P<0.05), as compared with the control group. In the Atherosclerosis + Knockdown group, serum levels of TNF-α (Figure 3(a)) and IL-1β (Figure 3(b)) significantly decreased (P<0.01), whereas the serum level of TGF-β1 (Figure 3(c)) significantly increased (P<0.01), as compared with the Atherosclerosis + Vector group. In the Atherosclerosis + Overexpression group, serum levels of TNF-α...
Figure 1: The circulating and aortic levels of chemerin increased in the progression of aortic atherosclerosis in ApoE−/− mice. (a) The aortic morphology staining by HE, oil red O, and immunofluorescence assay for chemerin at different stages (0, 4, 8, 12, and 16 W) in ApoE−/− mice fed with high-fat diet. (b), (c), and (d) The ratios of aortic neointima/media thickness, aortic plaque areas, and lipid percentages of aortic tissue at different stages. (e) Serum levels of chemerin investigated by ELISA at different stages. (f) The expression of chemerin in aortic tissues investigated by immunofluorescence assay at different stages. (g) Correlation analysis between aortic chemerin level and the ratio of aortic intima/media thickness. Scale bar: 0.1 mm. *P < 0.05, **P < 0.01 compared with 0 W.
Figure 2: Chemerin stimulated the aortic atherosclerosis in ApoE−/− mice. (a) The aortic morphology stained by HE and oil red in ApoE−/− mice fed with high-fat diet and transfected with adenovirus. (b) The mRNA level of aortic chemerin. (c) The protein level of aortic chemerin. (c–e) The ratios of aortic neointima/media thickness, aortic plaque areas, and lipid percentages of aortic tissue. Scale bar: 0.1 mm.

Figure 3: Chemerin increased the serum proinflammatory cytokines levels in ApoE−/− mice. (a, b) The serum levels of TNF-α and IL-1β were significantly raised by chemerin. (c) The serum level of TGF-β1 was significantly decreased by chemerin.
(Figure 3(a)) and IL-1β (Figure 3(b)) significantly increased ($P < 0.01$), whereas serum level of TGF-β1 (Figure 3(c)) significantly decreased ($P < 0.05$), as compared with the Atherosclerosis + Vector group.

Chemerin promoted the phosphorylation of p38 MAPK and expression of NF-κBp65. (a) The protein levels of NF-κBp65, PCNA, p-p38MAPK, p-JNK, and p-ERK1/2. (b–f) The mRNA levels of NF-κBp65, PCNA, p-p38MAPK, p-JNK, and p-ERK1/2.

In the Atherosclerosis + Vector group, the mRNA and protein expressions of NF-κBp65 (Figures 4(a) and 4(b)),
same as aortic plaque, chemerin expression was initially
for 8 weeks, which was most apparent at the 16th week. As
study, we found that aortic plaque arose with high-fat diet
disease, and cardiac dysfunction [10–13]. In the present
vascular diseases such as hypertension, coronary heart
diabetes+Overexpression group.

4. Discussion

Identified in cultured skin cells from the patients with
psoriasis, chemerin was originally correlated to maintain the
normal physiology of human skin [20]. Further investigation
revealed that chemerin is dominantly produced in the liver
and white adipose tissue, indicating the role of which as a
kind of adipokine [21]. Recent studies have implied that
chemerin is closely related to cardiovascular disease. The
levels of chemerin were significantly elevated in the synovial
fluid of patients with rheumatoid arthritis and could be
identified as a biomarker for rheumatoid arthritis [22]. In
these patients, increased circulating concentrations of
chemerin raised the risk for atherosclerosis [9]. Elevated
circulating levels of chemerin were also found in patients
with preeclampsia, metabolic syndrome, dilated cardiomy-
opathy, and carotid stenosis, indicating its role in cardio-
vascular diseases such as hypertension, coronary heart
disease, and cardiac dysfunction [10–13]. In the present
study, we found that aortic plaque arose with high-fat diet
for 8 weeks, which was most apparent at the 16th week. As
same as aortic plaque, chemerin expression was initially
found in aortic tissue of ApoE−/− mice at the 8th week, most
apparent at the 16th week. A positive relationship was
identified between the chemerin level in the aortic tissue and
aortic intimal hyperplasia, suggesting that chemerin is in-
volved in atherosclerotic plaque formation in ApoE−/− mice.
Interestingly, the circulating levels of chemerin initially
increased at 4th week and peaked at 8th weeks, which were
previous to the increasing of aortic chemerin levels. It can be
presumed that circulating chemerin was firstly raised due to
the obesity and fatty liver induced by high-fat diet feeding,
which subsequently led to the increase of chemerin in aortic
tissue.

Despite the evidence of anti-inflammation [23], chem-
erin was extensively acknowledged as a proinflammatory
cytokine. It was found that chemerin played important roles
in regulating immune and inflammatory responses mediated
by dendritic cells and natural killer cells [24]. In patients
with rheumatoid arthritis, serum levels of chemerin were
reduced by anti-TNF therapy, indicating its possible in-
volve in inflammation [25]. Chemerin promoted
the growth and invasion of gastric cancer cells by inducing
the phosphorylation of p38 MAPK and the expression of IL-6,
vascular endothelial growth factor (VEGF), and matrix
metalloproteinase-7 (MMP-7) [26]. The role of chemerin as a
proinflammatory cytokine was also demonstrated by the
evidence of chemerin-induced MMP production and endo-
thelial angiogenesis [27]. Our present results that elevation of
serum TNF-α and IL-1β induced by high fat diet feeding in
ApoE−/− mice were inhibited by knockdown of chemerin
supported the opinion that chemerin promotes inflammatory
response as a proinflammatory cytokine. However, the re-
relationship between the expression of chemerin in aortic tissue
and circulating levels of proinflammatory cytokines including
TNF-α and IL-1β remains unclear.

Three receptors named CMKLR1, G-protein coupled
receptor 1 (GPR1), and C-C motif receptor like 2 (CCRL2)
have been reported to bind chemerin [28–30]. It was
established that chemerin primarily mediates its functions
through CMKLR1 [31]. Besides in adipocytes [21], CMKLR1
has been successively detected in the adaptive immune
system including macrophages, natural killer cells, dendritic
cells, and leucocytes [24, 28, 32, 33]. Expressed in human
endothelial cells, CMKLR1 was activated by TNF-α, IL-1β,
and IL-6. Through this receptor, chemerin activated MAPK
and PI3K-AKT signal pathways to promote the proliferation,
differentiation, and migration of endothelial cells and induce
angiogenesis in vitro [16]. This angiogenesis induced by
chemerin can be abolished by the CMKLR1 inhibitor [34].
Acted at CMKLR1, but not GPR1, chemerin promoted
VSMC proliferation and increased blood pressure [35, 36].
In the isolated rat thoracic aorta, CMKLR1 agonist chem-
erin-9 caused arterial contraction in a dose-dependent
manner, while CMKLR1 antagonist CCX832 inhibited
phenylephrine-induced vasoconstriction [37]. Our previous
study indicated that the proliferation and migration of
VSMCs induced by platelet-derived growth factor (PDGF)
was inhibited by knockdown of CMKLR1 [18]. Our current
data suggested that chemerin stimulated the progression of
atherosclerosis by promoting p38 MAPK phosphorylation
and NF-κBp65 expression. We did not investigate the role
of CMKLR1 in chemerin-mediated plaque formation. Given
the evidences of CMKLR1 in vascular biology, it can be
speculated that CMKLR1 may play a role in the initiation
and progression of atherosclerosis.

In summary, we firstly identified that the circulating and
aortic levels of chemerin increased in the progression of
aortic atherosclerosis in ApoE−/− mice. Chemerin promoted
the initiation and progression of atherosclerosis.

Data Availability

The data used to support the findings of this study are
available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The study was supported by the NSFC foundation (81770496),
Medical Foundation of Guangdong (A2017145 and
2017ZC0451), Shenzhen Foundation (ICYJ20170307095947514),
and ZHFPC Foundation (201606012).
References

[1] D. Zhao, J. Liu, M. Wang, X. Zhang, and M. Zhou, “Epidemiology of cardiovascular disease in China: current features and implications,” Nature Reviews Cardiology, vol. 16, no. 4, pp. 203–212, 2018.

[2] D. Prabhakaran, P. Jeemon, and A. Roy, “Cardiovascular diseases in India,” Circulation, vol. 133, no. 16, pp. 1605–1620, 2016.

[3] R. Ross, “Atherosclerosis—an inflammatory disease,” New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999.

[4] P. Libby, P. M. Ridker, G. K. Hansson et al., “Inflammation in atherosclerosis,” Journal of the American College of Cardiology, vol. 54, no. 23, pp. 2129–2138, 2009.

[5] G. K. Hansson and P. Libby, “The immune response in atherosclerosis: a double-edged sword,” Nature Reviews Immunology, vol. 6, no. 7, pp. 508–519, 2006.

[6] G. Elena and L. Klaus, “Immune and inflammatory mechanisms of atherosclerosis,” Annual Review of Immunology, vol. 27, no. 1, pp. 165–197, 2009.

[7] J. J. Fuster, N. Ouchi, N. Gokce, and K. Walsh, “Obesity-induced changes in adipose tissue microenvironment and their impact on cardiovascular disease,” Circulation Research, vol. 118, no. 11, pp. 1786–1807, 2016.

[8] J. Kaur, H. S. Mattu, K. Chatha, and H. S. Randeva, “Chemerin in human cardiovascular disease,” Vascular Pharmacology, vol. 110, pp. 1–6, 2018.

[9] P. H. Dessein, L. Tsang, A. J. Woodiwiss, G. R. Norton, and A. Solomon, “Circulating concentrations of the novel adipokine chemerin are associated with cardiovascular disease risk in rheumatoid arthritis,” The Journal of Rheumatology, vol. 41, no. 9, pp. 1746–1754, 2014.

[10] H. Stepan, A. Philipp, I. Roth et al., “Serum levels of the adipokine chemerin are increased in preeclampsia during and 6 months after pregnancy,” Regulatory Peptides, vol. 168, no. 1-3, pp. 69–72, 2011.

[11] B. Dong, W. Ji, and Y. Zhang, “Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with metabolic syndrome,” Internal Medicine, vol. 50, no. 10, pp. 1093–1097, 2011.

[12] O. Zhang, Q. Ji, Y. Lin et al., “Circulating chemerin levels elevated in dilated cardiomyopathy patients with overt heart failure,” Clínica Chímica Acta, vol. 448, pp. 27–32, 2015.

[13] A. Kammerer, H. Staab, M. Herberg et al., “Increased circulating chemerin in patients with advanced cardioid stenosis,” BMC Cardiovascular Disorders, vol. 18, no. 1, p. 65, 2018.

[14] S. G. Sprioglu, C. G. Kostopoulos, J. N. Varakis, and H. H Papadaki, “Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis,” Journal of Atherosclerosis and Thrombosis, vol. 17, no. 2, pp. 115–130, 2010.

[15] M. R. Bennett, S. Sinha, and G. K. Owens, “Vascular smooth muscle cells in atherosclerosis,” Circulation Research, vol. 118, no. 4, pp. 692–702, 2016.

[16] M. A. Gimbrone Jr. and G. García-Cardeña, “Endothelial cell dysfunction and the pathobiology of atherosclerosis,” Circulation Research, vol. 118, no. 4, pp. 620–636, 2016.

[17] W. Xiong, Y. Luo, S. Dong et al., “Chemerin stimulates vascular smooth muscle cell proliferation and carotid neointimal hyperplasia by activating mitogen-activated protein kinase signaling,” PLoS One, vol. 11, no. 10, Article ID e0165305, 2016.

[18] H. Liu, W. Xiong, Q. Liu, J. Zhang, and S. Dong, “Chemokine-like receptor 1 regulates the proliferation and migration of vascular smooth muscle cells,” Medical Science Monitor, vol. 22, pp. 4054–4061, 2016.

[19] S. Dong, W. Xiong, J. Yuan, J. Li, J. Liu, and X. Xu, “MiRNA-146a regulates the maturation and differentiation of vascular smooth muscle cells by targeting NF-κB expression,” Molecular Medicine Reports, vol. 8, no. 2, pp. 407–412, 2013.

[20] S. Nagpal, S. Patel, H. Jacobe et al., “Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin,” Journal of Investigative Dermatology, vol. 109, no. 1, pp. 91–95, 1997.

[21] K. B. Goralski, T. C. McCarthy, E. A. Hanniman et al., “Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism,” Journal of Biological Chemistry, vol. 282, no. 38, pp. 28175–28188, 2007.

[22] K. Kaneko, Y. Miyabe, A. Takayasu et al., “Chemerin activates fibroblast-like synoviocytes in patients with rheumatoid arthritis,” Arthritis Research & Therapy, vol. 13, no. 5, p. R158, 2011.

[23] H. Yamawaki, S. Kameshima, T. Usui, M. Okada, and Y. Hara, “A novel adipocytokine, chemerin exerts anti-inflammatory roles in human vascular endothelial cells,” Biochemical and Biophysical Research Communications, vol. 423, no. 1, pp. 152–157, 2012.

[24] S. Parolini, A. Santoro, E. Maccarino et al., “The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues,” Blood, vol. 109, no. 9, pp. 3625–3632, 2007.

[25] M. M. Herenius, A. S. Oliveira, C. A. Wijbrands et al., “Anti-TNF therapy reduces serum levels of chemerin in rheumatoid arthritis: a new mechanism by which anti-TNF might reduce inflammation,” PLoS One, vol. 8, no. 2, Article ID e57802, 2013.

[26] C. Wang, W. K. K. Wu, X. Liu et al., “Increased serum chemerin level promotes cellular invasiveness in gastric cancer: a clinical and experimental study,” Peptides, vol. 51, pp. 131–138, 2014.

[27] J. Kaur, R. Adya, B. K. Tan, J. Chen, and H. S. Randeva, “Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis,” Biochemical and Biophysical Research Communications, vol. 391, no. 4, pp. 1762–1768, 2010.

[28] M. Samson, A. L. Edinger, P. Stordeur et al., “ChemR23, a putative chemoattractant receptor, is expressed in monocytic-derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-1 strains,” European Journal of Immunology, vol. 28, no. 5, pp. 1689–1700, 1998.

[29] G. Barnea, W. Strapps, G. Herrada et al., “The genetic design of signaling cascades to record receptor activation,” Proceedings of the National Academy of Sciences, vol. 105, no. 1, pp. 64–69, 2008.

[30] B. A. Zabel, S. Nakae, L. Zúñiga et al., “Mast cell-expressed orphan receptor CCR12 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis,” The Journal of Experimental Medicine, vol. 205, no. 10, pp. 2207–2220, 2008.

[31] A. Mattern, T. Zellmann, and A. G. Beck-Sickinger, “Processing, signaling, and physiological function of chemerin,” IUBMB Life, vol. 66, no. 1, pp. 19–26, 2014.

[32] V. Wittamer, J.-D. Fransen, M. Vulcano et al., “Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids,” The Journal of Experimental Medicine, vol. 198, no. 7, pp. 977–985, 2003.

[33] W. Vermi, E. Riboldi, V. Wittamer et al., “Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic
cells to lymphoid organs and inflamed skin,” *The Journal of Experimental Medicine*, vol. 201, no. 4, pp. 509–515, 2005.

[34] K. B. Neves, A. Nguyen Dinh Cat, R. A. M. Lopes et al., “Chemerin regulates crosstalk between adipocytes and vascular cells through nox,” *Hypertension*, vol. 66, no. 3, pp. 657–666, 2015.

[35] A. Kennedy, P. Yang, C. Read et al., “Chemerin elicits potent constrictor actions via chemokine-like receptor1 (CMKLR1), not G-protein-coupled receptor 1 (GPR1), in human and rat vasculature,” *Journal of the American Heart Association*, vol. 5, no. 10, Article ID e004421, 2016.

[36] H. Kunimoto, K. Kazama, M. Takai, M. Oda, M. Okada, and H. Yamawaki, “Chemerin promotes the proliferation and migration of vascular smooth muscle and increases mouse blood pressure,” *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 309, no. 5, pp. H1017–H1028, 2015.

[37] W. Stephanie, D. Anne, P. Mark et al., “Chemerin connects fat to arterial contraction,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 33, no. 6, pp. 1320–1328, 2013.